30 August 2016

Flintstone confirms Biocote float

As foreshadowed here in early November, investment company Flinstone Technologies, which today released interim figures, has revealed plans to float one of its investments, powder coatings outfit Biocote, on Aim next year.

Flintstone, which joined Aim in June raising £4.5 million net at 33p per share, has stakes in five different early-stage ventures, many originally developed by Russian scientists. In the six months to the end of September the group made a £669,000 operating loss, 17 per cent more than in the corresponding period in 2001.

The powdering process behind Biocote, which was created in Wolverhampton, creates hygienic surfaces for use in healthcare, food processing, white goods, such as fridges, and other appliances. An early stage investor was the first Oxford Technology Venture Capital Trust.

Flintstone picked up a 25 per cent stake in the group two years ago, subsequently increased to 40 per cent, and now wants to realise an exit by floating the company on Aim. At the end of last year Oxford Technology, which retains a 10 per cent stake in the group, valued Biocote at just £555,000.

Flintstone chairman Glyn Hirsch claims the company is 'nearing profitability' and now wants to raise more money in a placing to 'expand the business' and so is preparing the company for admission to Aim 'during the first half of 2003'.

Oxford Technology's second VCT has invested in another of Flintstone's companies, Hardide. This developer of super-resistant coating for metal machinery, which enhances their performance, is completing a £2 million fundraising, which will reduce Flinstone's stake from 55 per cent to 45 per cent.

Hardide, which is a Russian idea, is valued at £2 million. The fresh funds will enable it to buy manufacturing plant and move to fresh premises.

Another Russian enterprise, rechargeable battery developer Intellikraft, is struggling following the departure of Yuri Spirin as chief executive, who founded the company from scratch.

Flintstone's shares have fallen 13.5p, or over a third, to 19.5p since flotation. The company is currently worth £9.27 million, nearly twice its net asset value at these results of £4.98 million.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Retailers getting One View of their customers

One View listed on AIM via a reverse takeover back in March. It has developed software that provides retailers with a combined view of their customers history in both online and in-store shopping channels. This sort of digital engagement is a big opportunity for retailers to boost their sales.

Angle moves into the clinical trial stage

Angle is making good progress with its ‘Parsortix’ system which uses a precision-etched cassette to ‘sieve’ patient blood samples and capture cancerous tumour cells. The first major trial is now underway in ovarian cancer, led by the University of Vienna.

StatPro benefiting from a Revolution

StatPro shares have done well over the last month with the stock market giving the company credit for the growth in its new ‘Revolution’ product.

Tracsis signs key US deal

Transportation software specialist Tracsis has won a significant contract in the US. This looks like it could be a breakthrough which opens up the vast North American railroad market to this Leeds based company.

MedaPhor expands in ultrasound

MedaPhor came to the market two years ago and the £14 million market cap’s shares have done little since. However a couple of recent developments suggest they are worth keeping an eye on.

ScS sees no slowdown in sofas

ScS Group confirms it hasn't seen a slowdown in demand post-Brexit. Momentum has continued since the update in early June, with like-for-like sales order intake of 14.8 per cent for the first financial year ending in July.

More News